Clinical Features, Cancer Biology, Transplant Approach and Other Integrated Management Strategies for Wiskott–Aldrich Syndrome

References

• Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6):876–885. doi:10.1016/S0022-3476(05)82002-5
   PubMed Web of Science ®Google Scholar
• Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci. 2013;1285(1):26–43. doi:10.1111/nyas.12049
   Web of Science ®Google Scholar
• Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66. doi:10.2147/TACG.S58444
   Google Scholar
• Burroughs LM, Petrovic A, Brazauskas R, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020;135(23):2094–2105. doi:10.1182/blood.2019002939
   PubMed Web of Science ®Google Scholar
• Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104(13):4010–4019. doi:10.1182/BLOOD-2003-05-1592
   PubMed Web of Science ®Google Scholar
• Dupré L, Aiuti A, Trifari S, et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity. 2002;17(2):157–166. doi:10.1016/S1074-7613(02)00360-6
   Web of Science ®Google Scholar
• Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function. Dis Markers. 2010;29(3–4):157–175. doi:10.3233/DMA-2010-0735
   Web of Science ®Google Scholar
• Moratto D, Giliani S, Notarangelo LD, Mazza C, Mazzolari E, Notarangelo LD. The Wiskott-Aldrich syndrome: from genotype-phenotype correlation to treatment. Expert Rev Clin Immunol. 2007;3(5):813–824. doi:10.1586/1744666X.3.5.813
   PubMedGoogle Scholar
• Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006;117(4):725–738. doi:10.1016/j.jaci.2006.02.005
   PubMed Web of Science ®Google Scholar
• Symons M, Derry JMJ, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996;84(5):723–734. doi:10.1016/S0092-8674(00)81050-8
   Web of Science ®Google Scholar
• Stewart DM, Tian L, Nelson DL. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J Immunol. 1999;162(8):5019–5024.
   Web of Science ®Google Scholar
• Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456–464. doi:10.1182/blood-2003-05-1480
   PubMed Web of Science ®Google Scholar
• Ochs HD. The Wiskott-Aldrich syndrome. IMA. 2002;4:379–384.
   Google Scholar
• Bosticardo M, Marangoni F, Aiuti A, Villa A, Roncarolo MG. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113(25):6288–6295. doi:10.1182/blood-2008-12-115253
   PubMed Web of Science ®Google Scholar
• Patel PD, Samanich J, William Mitchell DM, Manwani D. A unique presentation of Wiskott–Aldrich syndrome in relation to platelet size. Pediatr Blood Cancer. 2011;56(7):1127–1129. doi:10.1002/pbc.22920
   Web of Science ®Google Scholar
• Skoric D, Dimitrijevic A, Cuturilo G, Ivanovski P. Wiskott-Aldrich syndrome with macrothrombocytopenia. Indian Pediatr. 2014;51(12):1015–1016. doi:10.1007/s13312-014-0550-5
   Web of Science ®Google Scholar
• Mazumdar J, Kanjilal S, Das A. Wiskott-Aldrich syndrome with normal-sized platelets in an eighteen-month-old boy: a rare mutation. J Pediatr Rev. 2015;3(2):10–13. doi:10.17795/jpr-417
   Google Scholar
• Bader-Meunier B, Proulle V, Trichet C, et al. Misdiagnosis of chronic thrombocytopenia in childhood. J Pediatr Hematol Oncol. 2003;25(7):548–552. doi:10.1097/00043426-200307000-00010
   PubMed Web of Science ®Google Scholar
• Suri D, Rikhi R, Jindal AK, et al. Wiskott Aldrich Syndrome: A Multi-Institutional Experience From India. Front Immunol. 2021;12:627651. doi:10.3389/fimmu.2021.627651
   Google Scholar
• Borte S, Fasth A, von Döbeln U, Winiarski J, Hammarström L. Newborn screening for severe T and B cell lymphopenia identifies a fraction of patients with Wiskott–Aldrich syndrome. Clin Immunol. 2014;155(1):74–78. doi:10.1016/J.CLIM.2014.09.003
   Web of Science ®Google Scholar
• Trifari S, Sitia G, Aiuti A, et al. Defective Th1 cytokine gene transcription in CD4 + and CD8 + T cells from Wiskott-Aldrich syndrome patients. J Immunol. 2006;177(10):7451–7461. doi:10.4049/jimmunol.177.10.7451
   Web of Science ®Google Scholar
• Shin CR, Kim MO, Li D, et al. Outcomes following hematopoietic cell transplantation for WiskottAldrich syndrome. Bone Marrow Transplant. 2012;47(11):1428–1435. doi:10.1038/bmt.2012.31
   PubMed Web of Science ®Google Scholar
• Chen N, Zhang ZY, Liu DW, Liu W, Tang XM, Zhao XD. The clinical features of autoimmunity in 53 patients with Wiskott–Aldrich syndrome in China: a single-center study. Eur J Pediatr. 2015;174(10):1311–1318. doi:10.1007/s00431-015-2527-3
   Web of Science ®Google Scholar
• Dupuis-Girod S, Medioni J, Haddad E. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features and outcome in a single center cohort of 55 patients. Pediatrics. 2003;111(5):e622–e627. doi:10.1542/peds.111.5.e622
   Web of Science ®Google Scholar
• Lee PPW, Chen TX, Jiang LP, et al. Clinical and molecular characteristics of 35 Chinese children with Wiskott-Aldrich syndrome. J Clin Immunol. 2009;29(4):490–500. doi:10.1007/s10875-009-9285-9
   Web of Science ®Google Scholar
• Mars LT, Araujo L, Kerschen P, et al. Invariant NKT cells inhibit development of the Th17 lineage. Proc Natl Acad Sci. 2009;106(15):6238–6243. doi:10.1073/pnas.0809317106
   Web of Science ®Google Scholar
• Perry GS, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892–1979). J Pediatr. 1980;97(1):72–78. doi:10.1016/S0022-3476(80)80133-8
   PubMed Web of Science ®Google Scholar
• Keszei M, Snapper SB, Westerberg LS, et al. Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive graphical abstract find the latest version: constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive. J Clin Invest. 2018;128(9):4115–4131. doi:10.1172/JCI64772
   Web of Science ®Google Scholar
• Cotelingam JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Invest. 1985;3(6):515–522. doi:10.3109/07357908509039813
   PubMed Web of Science ®Google Scholar
• Yoshida K, Minegishi Y, Okawa H, et al. Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol. 1997;14(October 1995):1–5.
   Google Scholar
• Liu GH, Chen J, Ji ZG, Zhou L. Expression of neural Wiskott-Aldrich syndrome protein in clear cell renal cell carcinoma and its correlation with clinicopathological features. Urol Int. 2015;95(1):79–85. doi:10.1159/000365595
   Web of Science ®Google Scholar
• Huang L, Lian J, Chen X, Qin G, Zheng Y, Zhang Y. WASH overexpression enhances cancer stem cell properties and correlates with poor prognosis of esophageal carcinoma. Cancer Sci. 2017;108(12):2358–2365. doi:10.1111/cas.13400
   Web of Science ®Google Scholar
• Martin TA, Pereira G, Watkins G, Mansel RE, Jiang WG. N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis. 2008;25(2):97–108. doi:10.1007/s10585-007-9120-8
   Web of Science ®Google Scholar
• Jin KM, Lu M, Liu FF, Gu J, Du XJ, Xing BC. N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis. Surg (United States). 2013;153(4):518–525. doi:10.1016/j.surg.2012.08.067
   Web of Science ®Google Scholar
• Bernabeu E, Josa M, Nomdedeu B, et al. One-step surgical approach of a thoracic aortic aneurysm in Wiskott-Aldrich syndrome. Ann Thorac Surg. 2007;83(4):1537–1538. doi:10.1016/j.athoracsur.2006.10.005
   Web of Science ®Google Scholar
• Wood G, Booth K, Khan Z, Biss T, Roysam C, Dark J. Descending aortic aneurysm in Wiskott-Aldrich syndrome: options for repair. Asian Cardiovasc Thorac Ann. 2017;25(9):635–637. doi:10.1177/0218492317738386
   Google Scholar
• Pellier I, Girod SD, Loisel D, et al. Occurrence of aortic aneurysms in 5 cases of Wiskott-Aldrich syndrome. Pediatrics. 2011;127(2):e498–e504. doi:10.1542/peds.2009-2987
   Web of Science ®Google Scholar
• Barutcu A, Goksel Leblebisatan SL, Metin Cil HI, Sasmaz FD, Sasmaz HI, Demir F. A case with Wiskott-Aldrich syndrome and ascending aorta aneurysm. J Pediatr Hematol Oncol. 2021;43:774–776. doi:10.1097/MPH.0000000000001932
   Web of Science ®Google Scholar
• He T, Cao K, Qi Z, et al. Acquired hemophilia A in Wiskott–Aldrich syndrome. J Clin Immunol. 2021;41:1119–1122. doi:10.1007/s10875-021-00978-9
   Web of Science ®Google Scholar
• Abhijit Anil Patil AD. Wiskott Aldrich syndrome having atypical presentation like Evans syndrome. Clin Pediatr (Phila). 2019;4:147.
   Google Scholar
• Kumar A, Jain S, Kumar P, Goyal JP. Generalised eczema: a diagnostic clue to Wiskott-Aldrich syndrome. BMJ Case Rep. 2021;14:242642. doi:10.1136/bcr-2021-242642
   PubMedGoogle Scholar
• Albert MH, Notarangelo LD, Ochs HD. Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol. 2011;18(1):42–48. doi:10.1097/MOH.0b013e32834114bc
   PubMed Web of Science ®Google Scholar
• Thrasher AJ. WASp in immune-system organization and function. Nat Rev Immunol. 2002;2(9):635–646. doi:10.1038/nri884
   PubMed Web of Science ®Google Scholar
• Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9(4):414–417. doi:10.1038/ng0495-414
   Google Scholar
• Schindelhauer D, Weiss M, Hellebrand H, et al. Wiskott-Aldrich syndrome: no strict genotype-phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product. Hum Genet. 1996;98(1):68–76. doi:10.1007/s004390050162
   Web of Science ®Google Scholar
• Worth AJ, Thrasher AJ. Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Rev Clin Immunol. 2015;11(9):1015–1032. doi:10.1586/1744666X.2015.1062366
   PubMed Web of Science ®Google Scholar
• Suri D, Singh S, Rawat A, et al. Clinical profile and genetic basis of Wiskott-Aldrich syndrome at Chandigarh, North India. Asian Pacific J Allerg Immunol. 2012;30(1):71–78.
   Web of Science ®Google Scholar
• Haskoloğlu Ş, Öztürk A, Öztürk G, et al. Clinical features and outcomes of 23 patients with Wiskott-Aldrich syndrome: a single-center experience. Turk J Hematol. 2020;37(4):271–281. doi:10.4274/tjh.galenos.2020.2020.0334
   Web of Science ®Google Scholar
• Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in management of the Wiskott-Aldrich syndrome: long term follow-up of 62 cases. Blood. 1993;82(10):2961–2966. doi:10.1182/blood.v82.10.2961.2961
   Web of Science ®Google Scholar
• Ozsahin H, Cavazzana-Calvo M, Notarangelo LD. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439–445. doi:10.1182/blood-2007-03-076679
   PubMed Web of Science ®Google Scholar
• Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 2011;118(6):1675–1684. doi:10.1182/blood-2010-11-319376
   PubMed Web of Science ®Google Scholar
• Jyonouchi S, Gwafila B, Gwalani LA, et al. Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome. Clin Immunol. 2017;179:47–53. doi:10.1016/J.CLIM.2017.02.001
   PubMed Web of Science ®Google Scholar
• Zaninetti C, Gresele P, Bertomoro A, et al. Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. Haematologica. 2020;105(3):820–828. doi:10.3324/haematol.2019.223966
   PubMed Web of Science ®Google Scholar
• Gabelli M, Marzollo A, Notarangelo LD, Basso G, Putti MC. Eltrombopag use in a patient with Wiskott–Aldrich syndrome. Pediatr Blood Cancer. 2017;64(12):1–3. doi:10.1002/pbc.26692
   Web of Science ®Google Scholar
• Gerrits AJ, Leven EA, Frelinger AL, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015;126(11):1367–1378. doi:10.1182/blood-2014-09-602573
   PubMed Web of Science ®Google Scholar
• Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet. 1968;2(7583):1364–1366. doi:10.1016/s0140-6736(68)92672-x
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97(6):1598–1603. doi:10.1182/blood.V97.6.1598
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott–Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Hematol. 2006;135:362–366. doi:10.1111/j.1365-2141.2006.06297.x
   PubMed Web of Science ®Google Scholar
• Pai SY, Notarangelo LD. Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment. Immunol Allergy Clin North Am. 2010;30(2):179–194. doi:10.1016/j.iac.2010.02.001
   PubMed Web of Science ®Google Scholar
• Shekhovtsova Z, Bonfim C, Ruggeri A, et al. A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. Haematologica. 2017;102(6):1112–1119. doi:10.3324/haematol.2016.158808
   PubMed Web of Science ®Google Scholar
• Elfeky RA, Furtado-Silva JM, Chiesa R, et al. One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. J Allergy Clin Immunol. 2018;142(5):1654–1656.e7. doi:10.1016/j.jaci.2018.06.042
   PubMed Web of Science ®Google Scholar
• Balashov D, Laberko A, Shcherbina A, et al. A conditioning regimen with plerixafor is safe and improves the outcome of TCRαβ + and CD19 + cell-depleted stem cell transplantation in patients with Wiskott-Aldrich syndrome. Biol Blood Marrow Transplant. 2018;24(7):1432–1440. doi:10.1016/j.bbmt.2018.03.006
   PubMed Web of Science ®Google Scholar
• Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115(16):3231–3238. doi:10.1182/blood-2009-09-239087
   PubMed Web of Science ®Google Scholar
• Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602–610.e11. doi:10.1016/j.jaci.2010.06.015
   PubMed Web of Science ®Google Scholar
• Gennery AR, Cant AJ. The immunocompromised host: the patient with recurrent infection. Adv Exp Med Biol. 2004;549:109–117. doi:10.1007/978-1-4419-8993-2_16
   Web of Science ®Google Scholar
• Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood. 2002;100(13):4344–4350. doi:10.1182/blood-2002-02-0583
   PubMed Web of Science ®Google Scholar
• Yue Y, Shi X, Song Z, et al. Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott–Aldrich syndrome. Pediatr Blood Cancer. 2018;65(8):1–5. doi:10.1002/pbc.27092
   Web of Science ®Google Scholar
• Mallhi KK, Petrovic A, Ochs HD. Hematopoietic stem cell therapy for Wiskott– Aldrich syndrome: improved outcome and quality of life. J Blood Med. 2021;12:435–447. doi:10.2147/JBM.S232650
   Web of Science ®Google Scholar
• Yamaguchi K, Ariga T, Yamada M, et al. Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression. Blood. 2002;100(4):1208–1214. doi:10.1182/blood-2002-01-0211
   Web of Science ®Google Scholar
• Slatter MA, Rao K, Abd Hamid IJ, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. 2018;24(3):529–536. doi:10.1016/j.bbmt.2017.11.009
   PubMed Web of Science ®Google Scholar
• Burroughs LM, Storb R, Leisenring WM, et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant. 2007;40(7):633–642. doi:10.1038/sj.bmt.1705778
   Web of Science ®Google Scholar
• Ngwube A, Hanson IC, Orange J, et al. Outcomes after allogeneic transplant in patients with Wiskott-Aldrich syndrome. Biol Blood Marrow Transplant. 2018;24(3):537–541. doi:10.1016/j.bbmt.2017.11.019
   Web of Science ®Google Scholar
• Stepensky P, Krauss A, Goldstein G, et al. Impact of conditioning on outcome of hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome. J Pediatr Hematol Oncol. 2013;35(6):234–238. doi:10.1097/MPH.0b013e318279cbfc
   Web of Science ®Google Scholar
• Kamani NR, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2011;17(12):1783–1789. doi:10.1016/j.bbmt.2011.05.008
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208–2216. doi:10.1182/blood.V94.7.2208.419k21_2208_2216
   PubMed Web of Science ®Google Scholar
• Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11(1):11–14. doi:10.1038/s41467-020-19505-2
   Web of Science ®Google Scholar
• Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome-long - term efficacy and genotoxicity (Science Translational Medicine). Sci Transl Med. 2014;6(254):1–15. doi:10.1126/scitranslmed.3010603
   Web of Science ®Google Scholar
• Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott–Aldrich syndrome. N Engl J Med. 2010;363(20):1918–1927. doi:10.1056/nejmoa1003548
   PubMed Web of Science ®Google Scholar
• Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313(15):1550–1563. doi:10.1001/jama.2015.3253
   PubMed Web of Science ®Google Scholar
• Ferrua F, Cicalese MP, Galimberti S, et al. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol. 2019;6(5):e239–e253. doi:10.1016/S2352-3026(19)30021-3
   PubMed Web of Science ®Google Scholar
• Morris EC, Fox T, Chakraverty R, et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood. 2017;130(11):1327–1335. doi:10.1182/blood-2017-04-777136
   PubMed Web of Science ®Google Scholar
• Sereni L, Castiello MC, Di Silvestre D, et al. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2019;144(3):825–838. doi:10.1016/j.jaci.2019.03.012
   PubMed Web of Science ®Google Scholar